

Improved electronic submission methodologies

Challenges and Future State

Ms Emma Richards
Assistant Director, Business Systems Review and Reporting Section,
Prescription Medicines Authorisation Branch, TGA

ARCS Annual Conference 2019





QUESTIONS

WHAT IS OUR GREATEST CHALLENGE IN THE ELECTRONIC DOSSIER MANAGEMENT SPACE?

HOW ARE WE TACKLING THIS CHALLENGE?





OUTLINE

- Define our greatest challenge
- Discuss how current work helps us tackle this challenge
- Look to the future





GREATEST CHALLENGE

WHAT IS OUR GREATEST CHALLENGE IN THE ELECTRONIC DOSSIER MANAGEMENT SPACE?

DATA


The greatest challenge we have is harnessing our data and presenting it in effective ways.





STATISTICS

Total Number of Sequences Received per Year



- Number of sequences of data is increasing year on year
- In 2019 we are set to reach over 10,000 sequences



GREATEST CHALLENGE

To harness our data we need to understand:



WHAT are the data requirements?

HOW will we obtain and analyse the data?

• WHY should we do this?



WHAT are the data requirements?

- IDENTIFY data needs
- ASSESS quality and suitability of current data sources





HOW will we obtain and analyse the data?


PART A: Obtain the data


- Delivered in a TIMELY MANNER
 - Web gateway
 - Process automation

- STRUCTURE and FORMAT suited to analysis
 - eCTD
 - Greater use of XML
 - Specifications (regional and ICH)



STATISTICS







HOW will we obtain and analyse the data? PART B: Analyse the data

- TECHNOLOGY
 - Artificial Intelligence (AI)
 - Deep Learning
 - Data visualisation programs

- LINKING the data
 - Determine the appropriate system for the data to be sourced



WHY should we do this?





Current State







Planning





Future State





WHY should we do this?

- To better use available technology
- To easily see the full story of each medicine
- To assist with evaluations and post-market requirements



WHY should we do this?

- To BETTER USE available technology
- To EASILY SEE the full story of each medicine
- To ASSIST with evaluations and post-market requirements





WHY should we do this?


To draw meaningful insights to assist in ensuring the ongoing safety, efficacy and quality of medicines.



LOOK TO THE FUTURE

The Future of electronic submissions in Australia

- Utilises emerging technology
- Provides enhanced support for decision making
- Streamlines dossier processing





LOOK TO THE FUTURE

How can you help?

- Ask questions, provide suggestions
- Feedback on upcoming guidance and specifications
- Tidy up look at transitioning to a single format with lifecycle history





LOOK TO THE FUTURE

How can you help?



Contact edr@health.gov.au to discuss further.



Australian Government

Department of Health

Therapeutic Goods Administration